Global Hypertension Drugs Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Hypertension Drugs Market Research Report 2024
The standard definition of high blood pressure is determined by the Joint National Committee (JNC) on Detection, Evaluation, and Diagnosis of High Blood Pressure. A person is considered to have high blood pressure after three to six elevated blood pressure measurements over several months. These definitions apply to adults who are healthy and not using medication for high blood pressure. If the two pressures fall in different categories, the higher one is used to determine the severity of hypertension.
According to Mr Accuracy reports’s new survey, global Hypertension Drugs market is projected to reach US$ million in 2034, increasing from US$ million in 2024, with the CAGR of % during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Hypertension Drugs market research.
With an increase in the population of older people, the market for hypertension drugs has a positive outlook over the forecast period. The prevalence of hypertension is high among the older population with close to 70% of the patients with high BP above the age of 60. Currently, close to 11% of the global population is aged 60 years or over and is estimated to reach nearly 22% by 2050. Since the risk of developing pulmonary hypertension increases with age, a growing older population will aid in the growth prospects of the hypertension drugs market in the coming years.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Hypertension Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Novartis
Daiichi Sankyo
Actelion Pharmaceuticals
Boehringer Ingelheim
Pfizer
Segment by Type
Calcium Channel Blockers
Diuretics
Beta Blockers Vasodilators
Angiotensin Converting Enzyme Inhibitors
Alpha Blockers
Angiotensin Receptor Blockers
Renin Inhibitors
Hospitals
Clinics
Others
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Hypertension Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Hypertension Drugs market is projected to reach US$ million in 2034, increasing from US$ million in 2024, with the CAGR of % during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Hypertension Drugs market research.
With an increase in the population of older people, the market for hypertension drugs has a positive outlook over the forecast period. The prevalence of hypertension is high among the older population with close to 70% of the patients with high BP above the age of 60. Currently, close to 11% of the global population is aged 60 years or over and is estimated to reach nearly 22% by 2050. Since the risk of developing pulmonary hypertension increases with age, a growing older population will aid in the growth prospects of the hypertension drugs market in the coming years.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Hypertension Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Novartis
Daiichi Sankyo
Actelion Pharmaceuticals
Boehringer Ingelheim
Pfizer
Segment by Type
Calcium Channel Blockers
Diuretics
Beta Blockers Vasodilators
Angiotensin Converting Enzyme Inhibitors
Alpha Blockers
Angiotensin Receptor Blockers
Renin Inhibitors
Segment by Application
Hospitals
Clinics
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Hypertension Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source